Discover investment opportunities in Top 5 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 5 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 5 Stocks Under $3 using our Smart AI Filter.
6 stocks found for "Top 5 Stocks Under $3"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.01 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
0.44 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
0.79 Risk measure | ±46.9% Price volatility | -62.2 Valuation | 0.00% Annual yield | |||
1.71 Risk measure | ±83.6% Price volatility | 46.2 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±88.4% Price volatility | -5.2 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors make OSTX attractive to penny stock investors?
A: OSTX presents potential for high returns given its low price point under $3, appealing to risk-tolerant investors. As penny stocks often come from smaller, growth-focused companies, OSTX may offer growth potential, but also carries significant risk due to market volatility and liquidity issues.
Q: Does HURA's performance correlate with commodity prices?
A: HURA, likely an ETF tied to commodities, may show performance correlation with underlying commodity prices. Since commodity prices can be volatile, this ETF may experience fluctuations, impacting investors’ returns. Research into specific commodities involved is recommended for deeper insight.
Q: How might ZSPC be affected by changes in tech regulations?
A: If ZSPC operates within the tech sector, regulatory changes could impact its operational strategies and market positioning. Tech regulations often influence innovation, competition, and data privacy, potentially affecting company growth.
Q: Is WRN a viable option for exposure to the mining sector?
A: WRN could offer exposure to the mining sector, with potential benefits from rising commodity demand. However, mining stocks can be subject to regulatory, environmental, and commodity price risks, making thorough analysis crucial for investors.
Q: What are the potential risks associated with investing in OKUR?
A: Investing in OKUR, as a sub-$3 stock, involves higher risk due to potential volatility and low market capitalization. Penny stocks like OKUR can face liquidity issues and may be susceptible to quick price shifts, requiring careful risk assessment.
Q: How does RVPH's volatility impact its investment appeal?
A: RVPH’s volatility may deter risk-averse investors but might attract those looking for rapid gains. High volatility indicates significant price movements, which, while risky, could result in notable returns if timed well.
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read more